AbbVie reports improved facial satisfaction among weight-loss drug users
At a glance
- $ABBV today−0.90%last $291.91
- Vs industry peers+0.30 pts6-peer median −1.20% · in step
- Since Nov 8−0.88%from the first trade after the story
- 52-week range3.6% below high$190.75 – $302.93
- Last reported profit$4.22Bquarter to Sep 30, 2026 · 10-Q
- Coverage0 this week6 in 30 days · quieter than usual
- Key person: Filed with SEC
- Clear: legal, regulatory, security, operational, financial integrity
Options price an average move of ±6.5% by Dec 18 — the at-the-money straddle, the typical size of the move; the bands are one standard deviation.
Early signals (1) — filed with the SEC or first reported, not yet widely covered
- Key person · SEC 8-K, Item 5.02, Nov 2: Filed: a director or officer departed, was appointed, or had their pay changed. View filing →
Close-to-close moves; beta-adjusted against the S&P 500, σ in the stock’s own daily noise; ranges one standard deviation. Reports are outlets’ words or SEC filings. Not a forecast or advice.
What it means
- What to watch: Single-product healthcare firms face the brunt of setbacks — one trial failure can overshadow the whole story.
- How the stock is trading: $ABBV -0.90% in the latest session.
- Timing: It was published over the weekend. The change shown is Friday's, and Monday is the first session that could react. Market holidays are not detected.
Where the stock stands
AbbVie ($ABBV) slipped 0.90% to $291.91 in the latest session. Over the past month it is up 3.6%. It now sits 3.6% under the 52-week high of $302.93 and 53% above the year's low of $190.75, close to the top of its range. The high sits 59% above the low, a wide range for one year.
What the filings say
In its latest report (10-Q, filed Nov 3, 2026), $ABBV earned $4.22B over the quarter to Sep 30, 2026 on revenue of $17.40B (+2.4% QoQ). Operations brought in $14.87B of cash over the nine months to Sep 30, 2026; after capital spending, free cash flow was $13.98B. Its most recent filings before this story: 10-Q on Nov 3, 2026, 8-K on Nov 2, 2026, 8-K on Oct 30, 2026. Figures are as filed with the SEC; the $ABBV page has the full statements.
How much coverage it is getting
This is one of 6 stories on AbbVie in Wook's last 30 days of coverage, including 0 this week. None came this week, so coverage has gone quiet. Going by their wording, 1 read bullish, 3 neutral and 2 bearish. This one reads bearish, along with a sizeable minority of them. Seeking Alpha wrote 5 of the 6 (83%), so the count reflects one outlet's output more than broad attention.
The bigger picture
Healthcare outcomes hinge on approvals, trial results, and pricing — one FDA decision or pricing shift can tip the scales for a drugmaker or the whole sector. Health Care reads calm on Wook's supply-chain scanner today, with no unusual stress in the filings and disclosures it watches.
What to watch next
The $ABBV page has the full chart, filings, and valuation model. Comparing outlets helps spot confirmation or repetition. Wook AI can pull live data and run the numbers on request — how far $ABBV is from its high, or how this week's coverage stacks up.
Discussion
No one has weighed in yet. Start the discussion on this story.
What happened after this published
Seeking Alpha published this on November 9, 2026. $ABBV has moved -0.88% ($294.50 to $291.91). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.
